Exela Pharma Sciences LLC filed a patent-infringement suit over Nivagen Pharmaceuticals Inc.’s recently approved generic version of Elcys and wants a temporary restraining order blocking its launch, which Exela says “would destroy the market” for the branded injection.
“Nivagen’s entry into the market is imminent as it has already begun contacting potential customers regarding offers for sale of its product and proposing a significant discount to the list price of Elcys,” according to a complaint filed Monday in the US District Court for the District of Delaware.
Elcys is a low-aluminum supplement of a key amino acid given to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.